Research looking into the feasibility of a novel biomarker for MASLD is being presented next week at The 75th Liver Meeting. The American Association of the Study of Liver Diseases (AASLD) meeting this year takes place from 15-19 November in San Diego, California.
Magnetic resonance imaging (MRI)-based liver volume is increasingly being used as a biomarker in metabolic dysfunction-associated steatotic liver disease (MASLD) clinical trials. Generally, a decrease in liver volume is interpreted as improvement, and is attributed to regression of steatosis when accompanied by a reduction in MRI proton density fat fraction (MRI-PDFF). Importantly, as levels of fibrosis increase with disease progression both steatosis and liver volume decrease, meaning that an interpretation of decreased liver volume as an improvement might not always be accurate.
The research being presented at AASLD investigated the feasibility of using an alternative biomarker, fat free liver volume. Removing the effect of steatosis on liver volume may more accurately reflect changes in the functioning parenchyma in pre-cirrhotic steatotic liver disease.
You can find the abstract details below.
Title: Feasibility of fat free liver volume as a biomarker in steatotic liver disease
Abstract/poster number: 875, 2122
Authors: Brännström E, Rorsman F, Vessby J, Hockings P, Johansson L
Session: Diagnostics and Biomarkers – MASH
Poster – Saturday, November 16 13:00-14:00 PST